Home/Chordia Therapeutics/Hiroshi Miyake, Ph.D.
HM

Hiroshi Miyake, Ph.D.

CEO

Chordia Therapeutics

Therapeutic Areas

Chordia Therapeutics Pipeline

DrugIndicationPhase
rogocekib (CTX-712)Oncology (unspecified)Phase 1/2
CTX-177 (ONO-7018)Immunology/OncologyPhase 1
CTX-439OncologyPreclinical/Research
CRD-1968099Oncology/ImmunologyPreclinical